Evidence map›Paper›PMID 29482311›Full record

ReviewInternational journal of stem cells2018

Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-analysis.

Hyunsuk Jeong, Hyeon Woo Yim, Hun-Jun Park, Youngseung Cho, Hanter Hong, Na Jin Kim, Il-Hoan Oh

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of stem cells, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05043610 (Transplantation of Mesenchymal Stem Cells for Prevention of Acute Myocardial Infarction Induced Heart Failure), which is not on this map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05043610 phase3completednot on this mapstarted 2021, after this paper: background citation

Transplantation of Mesenchymal Stem Cells for Prevention of Acute Myocardial Infarction Induced Heart Failure: a Phase III Randomized Clinical Trial

TypeinterventionalSponsorShiraz University of Medical SciencesRan2021 to 2024Enrolled420ConditionsMyocardial Infarction, Acute, Myocardial Infarction First, Myocardial Infarction, Anterior Wall, Cardiac Remodeling, VentricularArmsUmbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs), Conventional Treatment
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hyunsuk JeongDepartment of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyeon Woo YimDepartment of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hun-Jun ParkDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Youngseung ChoDepartment of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hanter HongCheong-yang Branch Office of the Community Health Center, Cheongyang, Korea.
Na Jin KimMedical Library, The Catholic University of Korea, Seoul, Korea.
Il-Hoan OhCatholic High-Performance Cell Therapy Center & Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMesenchymal stem cells (MSC) have emerged as breakthrough treatments for myocardial infarction. However, the efficacy of MSC remains unclear. The aim of the study was to evaluate treatment effect of MSC in terms of mechanical, regenerative, and clinical outcomes for patients with myocardial infarction (MI) using meta-analysis.

methodsA systematic search and critical review of MEDLINE, EMBASE, and Cochrane database literature published from inception through December 2017 was performed. The inclusion criteria were randomized controlled trials, studies on patients with myocardial infarction, and studies compared with placebo as a control group.

resultsA total of 950 patients from 14 randomized placebo controlled trials were included in the final meta-analysis. MSC treatment showed benefits for mechanical, regenerative, and clinical outcomes. In terms of mechanical outcomes, the LVEF of the MSC treatment group increased by 3.84% (95% CI: 2.32~5.35,

conclusionsThe findings of this meta-analysis indicate that MSCs can be beneficial in improving heart function in the treatment of MI. However, the efficacy of MSCs must be further explored through large randomized controlled trials based on rigorous research design.

Indexed as

Mesenchymal stem cellMeta-analysisMyocardial infarctionSystematic review

Identifiers

PMID29482311
PMCPMC5984054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.